Endonuclease News and Research

RSS

Genentech announces Phase III study results of baloxavir marboxil in people at high risk of flu

Genentech, a member of the Roche Group, today announced that the Phase III CAPSTONE-2 study showed treatment with baloxavir marboxil significantly reduced the time to improvement of influenza symptoms versus placebo in people at high risk of serious complications from the flu, which includes adults 65 years of age or older, or those who have conditions such as asthma, chronic lung disease, morbid obesity, or heart disease.

4 Oct 2018

DermTech completes enrollment in clinical study to assess DNA damage and reversal

DermTech, Inc., the global leader in non-invasive molecular dermatology, announced today it has completed enrollment in a clinical study to assess DNA damage induced by an excimer laser and evaluate the potential of topical agents T4 endonuclease and photolyase to reduce DNA damage induced as measured through gene expression analysis.

19 Sep 2018

Single dose of influenza drug can shorten duration of illness, study reveals

A single dose of a new influenza drug can significantly shorten the duration of the illness in teens and adults, according to a study published in the prestigious New England Journal of Medicine.

6 Sep 2018

Bluebird bio collaborates with Gritstone Oncology to develop novel cancer cell therapies

Bluebird bio, Inc. and Gritstone Oncology, Inc. today announced a collaboration to research, develop and commercialize products for the treatment of cancer using cell therapy.

23 Aug 2018

Researchers examine new influenza drug's mode of action in detail

The new influenza drug Xofluza, developed by the Japanese pharmaceutical company Shionogi, was approved for clinical use in Japan in February 2018.

26 Jun 2018

Gene editing tool used to detect cancer

Researchers have developed a DNA detection system that can detect the presence of bacterial and viral DNA, which could be a valuable diagnostic tool for a range of disorders.

16 Feb 2018

Scientists identify special pair of RNA scissors with many functions

CRISPR/Cas systems are known as promising "gene scissors" in the genome editing of plants, animals, and microorganisms by targeting specific regions in their DNA - and perhaps they can even be used to correct genetic defects.

8 Feb 2018

Cellectis wins European patent for CRISPR use in T-cells

Cellectis, a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited CAR T-cells (UCART), today announced the grant by the European Patent Office of patent No. EP3004337 for the invention of using RNA-guided endonucleases, such as Cas9 or Cpf1 for the genetic engineering of T-cells.

24 Jul 2017

Researchers discover how new molecular scissors unzip and cleave DNA with high accuracy

Researchers from the University of Copenhagen (Denmark), led by the Spanish researcher Guillermo Montoya, have discovered how Cpf1, new molecular scissors unzip and cleave DNA.

6 Jul 2017

Study discovers new role for DNA2 enzyme in repair process

A biochemical analysis study has discovered a new role for the DNA2 enzyme.

6 Apr 2017

IDT offers cost-effective and most complete spectrum of CRISPR genome editing systems

Reflecting its drive to provide innovative solutions to the genomics community, Integrated DNA Technologies (IDT) is the first genomics company to develop and bring to market a complete ribonucleoprotein-based Cpf1 CRISPR system.

2 Feb 2017

St. Jude scientists develop insights to guide development of powerful novel anti-influenza drugs

By analyzing the molecular details of how artificially created drug-resistant flu strains manage to survive treatment, St. Jude Children's Research Hospital scientists have developed insights to guide development of powerful new anti-influenza drugs. These compounds will target a viral enzyme critical to the virus' proliferation in the body.

15 Mar 2016

Researchers identify common molecular alteration in glioblastoma

Glioblastoma is the most aggressive manifestation of brain tumours. Due to its high invasive capacity and uncontrolled, infiltrating growth, it is particularly difficult to manage. Currently, the treatment for this disease consists of a combination of surgery (when possible), radiation and chemotherapy.

22 Feb 2016

Study sheds further light on the way APOL1 protein kills trypanosmoe

The African trypanosome Trypanosoma brucei is a blood parasite capable of infecting many mammals. Humans are provided with natural immunity against infection through the activity of the protein apolipoprotein L1 (APOL1): captured via endocytosis, APOL1 forms pores in the lysosomal membrane, leading to the death of the trypanosome.

27 Aug 2015

Researchers freeze biological structures to illustrate DNA double-strand break process

Scientists from the Spanish National Cancer Research Centre, led by Guillermo Montoya, have developed a method for producing biological crystals that has allowed scientists to observe --for the first time-- DNA double chain breaks. They have also developed a computer simulation that makes this process, which lasts in the order of millionths of a second, visible to the human eye.

9 Dec 2014

Scientists reproduce chromosomal modifications in human cells that cause certain cancer

Scientists at the Centro Nacional de Investigaciones Cardiovasculares (CNIC) and the Centro Nacional de Investigaciones Oncol-gicas (CNIO) have succeeded in reproducing, in human cells, the chromosomal translocations that cause two types of cancer: acute myeloid leukemia and Ewing's sarcoma.

5 Jun 2014

Researchers reproduce tumor chromosomal translocations in human cells

Scientists from the Spanish National Cancer Research Centre and the Spanish National Cardiovascular Research Centre have been able to reproduce, for the first time in human cells, chromosomal translocations associated with two types of cancer: acute myeloid leukaemia and Ewing's sarcoma.

4 Jun 2014

Protein expression predicts postop NSCLC recurrence, survival

US-based researchers have identified a panel of 12 proteins that may help predict overall survival and the risk of recurrence in patients treated with surgery for non-small-cell lung cancer.

15 Apr 2014

Teen researcher wins top award from Intel Foundation for research on potential drugs to treat influenza

From new cancer treatments to an exploration of how technology affects the adolescent brain, the innovative research of America's future scientists, engineers and inventors took center stage in the nation's capital today.

12 Mar 2014

Curie-Cancer inks partnership agreements with Meiogenix to develop SpiX technology

Curie-Cancer, the body responsible for developing Institut Curie's industry partnership activity, today announces two three-year partnership agreements with Meiogenix, a French SME. Meiogenix develops SpiX technology under license from Institut Curie and Institut National de la Recherche Agronomique.

19 Nov 2013